Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 28, 2025

πŸš€ PHAXIAM Therapeutics($PHXM) SA Soars +18.82%: A Biotech Penny Stock Star! 🌟

PHAXIAM Therapeutics SA Skyrockets +18.82%! Dive into this biotech penny stock's stellar week and the industry's broader movements. πŸ“ˆπŸ”¬

Β If you're interested in AI trading and want to explore the top 10 AI robots, you can find them at the following links:

  1. Top 10 AI RobotsΒ  - SORT BY SharperΒ 
  2. Top 10 AI RobotsΒ 
  3. Top 10 AI RobotsΒ 

These AI robots are designed to provide insights and strategies to enhance your trading experience. Feel free to explore them and discover how AI can empower your trading decisions. πŸ€–πŸ“ˆΒ Β  Β Discover the Top 10 AI Robots!Β πŸ“Š

$PHXM

πŸ“Š Market Snapshot:

  • Biotech Overview: Out of 920 stocks in the Biotechnology Industry, 273 (29.64%) showed an uptrend, while the majority, 647 (70.36%), were on a downtrend. This indicates a mixed market sentiment in this sector.

  • Weekly Winners πŸ“ˆ: PHXM leads the pack with a whopping +strong performance, followed by OBIO (+88%), the highest price gainer. Unfortunately, SEEL saw the biggest dip, declining -67%.

  • Volume Dynamics πŸ“Š: Volume across the industry decreased by 13% weekly, but has shown a promising growth over the past month (+26%) and quarter (+32%).

πŸ”¬ A Deep Dive into Biotech:

The world of Biotechnology is truly vast. From genetic and protein engineering to producing cutting-edge medicines and therapies, biotech is at the forefront of medical innovation. Its primary goal? Combatting diseases and enhancing health. But the journey isn't easy. Each discovery must undergo rigorous tests, often taking years, before receiving the nod from regulatory bodies like the U.S. FDA.

Top players in the industry include household names like Amgen Inc., Gilead Sciences, Inc., and Celgene Corporation.

πŸ“ˆ$PHXM's Impressive Week:

PHXM, trading at a price of $5.24, stood out this week with a commendable gain of +18.82%. Over the past five trading days, the stock rose +10.94% on an average daily volume of 14,667 shares. However, investors should be cautious, as the stock saw a drawdown of -29.89% during the same period.

If you're considering hedging strategies, take note: A.I.dvisor has pointed out that PHXM has a low correlation with RETA, meaning they've only moved in tandem about 26% of the time over the last year.

πŸ” Fundamental Analysis Ratings:

  • Valuation Rating: 50
  • P/E Growth Rating: 86
  • Price Growth Rating: 62
  • SMR Rating: 93
  • Profit Risk Rating: 95
  • Seasonality Score: -26 (A score ranging between -100 and +100)

The biotechnology sector remains an exciting field with ample opportunities for investors, especially with penny stocks like PHXM showing robust growth. While the industry exhibits volatility, with thorough research and due diligence, one can potentially find hidden gems. Always remember to diversify and consult with a financial advisor before making investment decisions.

Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.
Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.